REGULATORY INTELLIGENCE·EMA Action
Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition
Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.
90-Day Activity